Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95
- PMID: 18512812
- DOI: 10.1002/art.23498
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95
Abstract
Objective: Analysis of peripheral B cell subsets in patients with systemic lupus erythematosus (SLE) has provided evidence of specific alterations, such as an expansion of CD27++ plasma cells/blasts and transitional B cells. However, memory B cells in lupus have not been thoroughly investigated, and only recently a CD27- memory B cell subset was identified in the peripheral blood of lupus patients. Focusing on CD27- B cells, this study aimed to identify abnormalities in peripheral B cell subsets in patients with SLE.
Methods: Three independent cohorts of lupus patients were used to characterize CD27- memory B cells, using multiparameter flow cytometry and single-cell reverse transcription-polymerase chain reaction of heavy-chain transcripts.
Results: We identified a homogeneous subset of CD27-,IgD-,CD95+ memory B cells with an activated phenotype that was increased in patients with disease flares and that correlated with disease activity and serologic abnormalities. In contrast, the entire subset of CD27-,IgD- B cells was found to be heterogeneous, did not correlate significantly with lupus activity, and was also increased in patients with bacterial infections.
Conclusion: We conclude that CD95 is a useful marker to identify CD27- memory B cells with an activated phenotype, which might serve as a biomarker for lupus activity and as a target of further investigations aiming to elucidate the pathogenic potential of these cells and the mechanisms involved in the generation as well as regulation of this CD27-,IgD-,CD95+ memory B cell subset.
Similar articles
-
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.Arthritis Rheum. 2003 May;48(5):1332-42. doi: 10.1002/art.10949. Arthritis Rheum. 2003. PMID: 12746906
-
Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells.Arthritis Rheum. 2004 Jun;50(6):1918-27. doi: 10.1002/art.20274. Arthritis Rheum. 2004. PMID: 15188368
-
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.Arthritis Rheum. 2002 Aug;46(8):2160-71. doi: 10.1002/art.10445. Arthritis Rheum. 2002. PMID: 12209521
-
Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus.Lupus. 2004;13(5):283-9. doi: 10.1191/0961203304lu1014oa. Lupus. 2004. PMID: 15230280 Review.
-
B cells and immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged humans.Ageing Res Rev. 2011 Apr;10(2):274-84. doi: 10.1016/j.arr.2010.12.002. Epub 2010 Dec 23. Ageing Res Rev. 2011. PMID: 21185406 Review.
Cited by
-
Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus.Cell Mol Immunol. 2016 Nov;13(6):764-775. doi: 10.1038/cmi.2015.48. Epub 2015 Jul 6. Cell Mol Immunol. 2016. PMID: 26144250 Free PMC article.
-
B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.Int J Mol Sci. 2024 Oct 9;25(19):10845. doi: 10.3390/ijms251910845. Int J Mol Sci. 2024. PMID: 39409173 Free PMC article.
-
Measurement of circulating CD21-CD27- B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers.Sci Rep. 2022 Jun 2;12(1):9189. doi: 10.1038/s41598-022-12775-4. Sci Rep. 2022. PMID: 35654865 Free PMC article.
-
B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.Clin Ther. 2018 Jun;40(6):1034-1045. doi: 10.1016/j.clinthera.2018.04.016. Epub 2018 May 23. Clin Ther. 2018. PMID: 29801753 Free PMC article. Review.
-
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.Arthritis Res Ther. 2017 May 15;19(1):91. doi: 10.1186/s13075-017-1284-2. Arthritis Res Ther. 2017. PMID: 28506291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials